The Lankenau Institute for Medical Research
Cancer research is a broad field that encompasses many basic and medical sciences. Our work extends from genes to drugs to improve the prognosis and treatment of cancer. In collaboration with clinical oncologists in the Cancer Centers at Lankenau Medical Center and other Main Line Hospitals, we focus our main efforts on common tumors of the breast, lung, gastrointestinal tract, ovary and prostate.
Genes that affect cancer severity are a distinct theme of basic research at LIMR. These genes serve as a conceptual hub for the discovery and development of new prognostic markers and drugs to render tumors more susceptible to attack. Arising from this distinct theme, the new drugs act broadly to stimulate the immune system, arrest metastasis, starve key nutrients, or disrupt essential metabolic pathways. Rounding out these efforts, which are at various stages of preclinical and clinical development, we also investigate new surgical methods and radiation strategies to eradicate tumors.
Scott Dessain, MD, PhD (LIMR Center for Human Antibody Technology [CHAT]) – native human antibodies, mAb cloning, botulinum neurotoxin
Susan K. Gilmour, PhD – polyamines, skin tumorigenesis, wound repair, Myo/Nog cells, thrombosis, cancer, inflammation
Alexander J. Muller, PhD – tumor environment, small molecule inhibitors, immunotherapy, stem cells
James M. Mullin, PhD – gastroenterology, tight junction, transepithelial permeability, gastrointestinal physiology, transport physiology, epithelial physiology, gastrointestinal cancer, epithelial barrier function
George C. Prendergast, PhD – immunotherapy, immune escape, immune surveillance, cancer genetics, preclinical models, experimental therapeutics
Janet Sawicki, PhD – ovarian, cervical, pancreatic, prostate, lung, MAC disease, nanotherapy